The global NK cell therapy market was valued at USD 265.0 million in 2025. The market is estimated at USD 320.0 million in 2026 and is projected to reach USD 3.85 billion by 2036, at a CAGR of 28.2% during the forecast period 2026-2036. This report provides a detailed assessment of the market, covering NK cell immunology, persistence and dosing, regulatory pathways, manufacturing and supply, pricing and reimbursement, the developer landscape, and future growth opportunities.
The market includes unmodified, CAR-modified, gene-edited, and cytokine-induced memory-like natural killer cell therapies made from cord blood, peripheral blood, induced pluripotent stem cell (iPSC) lines, and established cell lines for hematological cancers, solid tumors, infectious diseases, and autoimmune diseases. As no NK cell product is approved yet, revenue is counted at the value of cells supplied into trials, contracted manufacturing and process development, and treatment given under national frameworks ahead of a marketing authorization. CAR-T and engineered TCR therapies, tumor-infiltrating lymphocytes, NK cell engagers, standalone cytokine products, stem cell transplantation, private cord blood banking, culture reagents and equipment, and supportive care are excluded.
No natural killer cell therapy appears yet on the FDA's list of approved cellular and gene therapy products, where all approved CAR products and the only approved engineered TCR therapy are autologous T cell treatments. Growth in the NK cell therapy market is therefore weighted toward the later years of the forecast, as product revenue only follows approval. In July 2026, South Korea's Ministry of Health and Welfare moved treatment with a patient's own immune cells, including autologous NK cells, from medium to low risk and dropped the mandatory preliminary clinical study. According to the Ministry, of the 65 advanced regenerative medicine clinical studies approved in the country by June 2026, 13 were classed as low risk, 30 as medium risk, and 22 as high risk, meaning 80% fell in the medium- and high-risk classes.
NK cells are cleared within days to weeks instead of expanding and staying active for months, and this short persistence is the key reason no product has yet met the approval standard. It cannot be engineered out without bringing back the graft-versus-host risk and heavy conditioning the platform avoids. Multi-dose courses also multiply the material each patient needs, so capacity requirements rise sharply, and donor-dependent sources add qualification work for every batch. Developers must also prove benefit without persistence, and payers will weigh a full multi-dose course against a one-time CAR-T infusion on total cost and total benefit.
CAR-NK products that combine directed targeting with donor-derived supply are the largest opportunity, especially when paired with cytokine support. Antibody combinations in indications where an antibody is already standard of care, memory-like and interleukin-15 supported cells, and autologous treatment under Asian frameworks also offer clear openings. Key trends include the shift of development capital to receptor-modified cells, acceptance of repeat dosing as the standard regimen, and a move in starting material from cord blood and peripheral blood toward iPSC lines and cell lines that can be produced to a schedule.
By product type, the NK cell therapy market is segmented into unmodified NK cells, CAR-NK cells, gene-edited NK cells, and cytokine-induced memory-like NK cells. Unmodified NK cells hold the largest share in 2026, as this is the form in which the platform first reached the clinic, it remains the product used in most antibody combination studies, and it is the form supplied for pre-authorization treatment. CAR-NK cells are set to record the highest CAGR, because a CAR points the cells at a defined antigen instead of relying on innate recognition, the approach follows the CAR-T model regulators have already approved while keeping the safety of donor NK cells, and receptor-modified programs now draw most development capital. Gene-edited cells target checkpoint and signaling pathways that dampen activity, while memory-like cells are designed to stay active for longer.
By cell source, the NK cell therapy market is segmented into cord blood derived, peripheral blood derived, induced pluripotent stem cell (iPSC) derived, cell line derived, and other sources. Cord blood derived products lead in 2026, since cord blood needs no elective donor procedure, banks make units available without a new collection for each batch, and many clinical programs use it. iPSC-derived products are set to grow the fastest, as one edited line can be expanded indefinitely, consistency comes from the process rather than the donor, and scheduled supply suits multi-dose regimens. Cell lines offer unlimited uniform supply but must be irradiated before infusion, which limits their activity.
By cell origin, the NK cell therapy market is segmented into allogeneic and autologous. Allogeneic products hold the largest share in 2026 and are also set to grow the fastest, as donor NK cells do not cause graft-versus-host disease, a single batch can serve many patients, and products can be stocked and shipped ahead of need. Autologous treatment keeps a role where national rules allow clinic-based treatment before approval, mainly in South Korea and Japan, but each patient needs a separate collection and production run.
By indication, the NK cell therapy market is segmented into hematological malignancies (acute myeloid leukemia, lymphoma, and multiple myeloma), solid tumors, infectious diseases, autoimmune diseases, and other indications. Hematological malignancies lead in 2026, as evidence is easiest to generate in blood cancers, infused cells reach the disease without penetrating a tumor mass, and most trials run in these settings. Solid tumors are set to record the highest CAGR, since tumor cells that lower HLA expression to escape T cells become easier NK cell targets, T cell approaches have struggled in many solid cancers, and patient numbers are far larger. Infectious disease programs focus on viral infections in immunocompromised patients.
By combination approach, the NK cell therapy market is segmented into monotherapy, combination with monoclonal antibodies, combination with checkpoint inhibitors, and combination with cytokines. Monotherapy holds the largest share in 2026, as early trials first need to show the cells are active on their own. Antibody combinations are set to grow the fastest, because NK cells drive antibody-dependent cellular cytotoxicity, the infused dose strengthens an antibody already in use, and the therapy fits a pathway clinicians and payers accept. Cytokine combinations such as interleukin-15 extend the period the cells stay active.
By end user, the NK cell therapy market is segmented into hospitals & cancer centers, specialty clinics, and academic & research institutes. Hospitals & cancer centers lead in 2026, since trials run at sites with cell therapy expertise and infusions need conditioning and close monitoring. Specialty clinics are set to grow the fastest, as low graft-versus-host risk and lighter conditioning allow treatment outside a transplant unit, and parts of Asia permit clinic-based treatment before approval. Academic and research institutes also hold a meaningful part of current activity.
North America holds the largest share of the global NK cell therapy market in 2026. The region hosts most development programs and trials, the manufacturing and process development spending that supports them, and the treating centers with the deepest cell therapy experience, even though the FDA has not yet approved an NK cell product. The U.S. accounts for nearly all of the regional market, while Canada contributes mainly through academic programs.
Asia-Pacific is set to grow at the highest CAGR, supported by frameworks that allow treatment before marketing authorization, including South Korea's 2026 reclassification of autologous immune cell treatment and Japan's conditional pathway for regenerative medicine products. South Korea and Japan lead the region, and China adds a large number of clinical programs. Treatment volumes in Asia-Pacific exceed those in North America, but clinic-delivered treatment is priced well below clinical-stage supply. Europe's position rests on academic centers and programs in the Netherlands, Germany, and the Nordic countries, while Latin America and the Middle East & Africa remain small markets served by a limited number of private clinics.
The NK cell therapy market consists almost entirely of clinical-stage developers, best grouped by the cell source they use: iPSC lines that supply material to a schedule, cord blood backed by existing banks, and peripheral blood for autologous treatment under national frameworks. Large pharmaceutical companies mostly take part through partnerships and licensing. With products aimed at different antigens, indications, and combinations, companies currently compete for funding, clinical sites, and antibody partners, not for patients. Supply reliability across a multi-dose course is the main differentiator, followed by persistence evidence and antibody partnerships, and the first approval is expected to set the evidence standard and reference regimen for the field.
Key companies profiled in the report include Fate Therapeutics, Inc. (U.S.), Nkarta, Inc. (U.S.), Century Therapeutics, Inc. (U.S.), Artiva Biotherapeutics, Inc. (U.S.), ImmunityBio, Inc. (U.S.), NKGen Biotech, Inc. (U.S.), Celularity Inc. (U.S.), Indapta Therapeutics, Inc. (U.S.), Wugen, Inc. (U.S.), Shoreline Biosciences, Inc. (U.S.), Gamida Cell Ltd. (Israel), Glycostem Therapeutics B.V. (Netherlands), Takeda Pharmaceutical Company Limited (Japan), Takara Bio Inc. (Japan), and GC Cell Corporation (South Korea).
The market includes unmodified, CAR-modified, gene-edited, and cytokine-induced memory-like natural killer cell therapies made from cord blood, peripheral blood, induced pluripotent stem cell (iPSC) lines, and established cell lines for hematological cancers, solid tumors, infectious diseases, and autoimmune diseases. As no NK cell product is approved yet, revenue is counted at the value of cells supplied into trials, contracted manufacturing and process development, and treatment given under national frameworks ahead of a marketing authorization. CAR-T and engineered TCR therapies, tumor-infiltrating lymphocytes, NK cell engagers, standalone cytokine products, stem cell transplantation, private cord blood banking, culture reagents and equipment, and supportive care are excluded.
No natural killer cell therapy appears yet on the FDA's list of approved cellular and gene therapy products, where all approved CAR products and the only approved engineered TCR therapy are autologous T cell treatments. Growth in the NK cell therapy market is therefore weighted toward the later years of the forecast, as product revenue only follows approval. In July 2026, South Korea's Ministry of Health and Welfare moved treatment with a patient's own immune cells, including autologous NK cells, from medium to low risk and dropped the mandatory preliminary clinical study. According to the Ministry, of the 65 advanced regenerative medicine clinical studies approved in the country by June 2026, 13 were classed as low risk, 30 as medium risk, and 22 as high risk, meaning 80% fell in the medium- and high-risk classes.
Market Dynamics
Donor NK cells do not trigger graft-versus-host disease, which makes off-the-shelf supply the main driver of the NK cell therapy market: a product made from one donor can treat unrelated patients without the gene editing that allogeneic T cell programs need, one batch can serve many patients, and treatment can start as soon as the product ships. Combination with antibodies is a second driver, because NK cells carry out antibody-dependent cellular cytotoxicity and an infused dose adds effector capacity to an antibody the patient already receives. iPSC lines that are edited once and expanded without limit support repeat dosing, and pathways in South Korea and Japan allow treatment and evidence generation before a conventional approval.NK cells are cleared within days to weeks instead of expanding and staying active for months, and this short persistence is the key reason no product has yet met the approval standard. It cannot be engineered out without bringing back the graft-versus-host risk and heavy conditioning the platform avoids. Multi-dose courses also multiply the material each patient needs, so capacity requirements rise sharply, and donor-dependent sources add qualification work for every batch. Developers must also prove benefit without persistence, and payers will weigh a full multi-dose course against a one-time CAR-T infusion on total cost and total benefit.
CAR-NK products that combine directed targeting with donor-derived supply are the largest opportunity, especially when paired with cytokine support. Antibody combinations in indications where an antibody is already standard of care, memory-like and interleukin-15 supported cells, and autologous treatment under Asian frameworks also offer clear openings. Key trends include the shift of development capital to receptor-modified cells, acceptance of repeat dosing as the standard regimen, and a move in starting material from cord blood and peripheral blood toward iPSC lines and cell lines that can be produced to a schedule.
Segment Analysis
The report analyzes the market by product type, cell source, cell origin, indication, combination approach, end user, and geography, helping stakeholders identify the most attractive areas for development, partnering, and investment.By product type, the NK cell therapy market is segmented into unmodified NK cells, CAR-NK cells, gene-edited NK cells, and cytokine-induced memory-like NK cells. Unmodified NK cells hold the largest share in 2026, as this is the form in which the platform first reached the clinic, it remains the product used in most antibody combination studies, and it is the form supplied for pre-authorization treatment. CAR-NK cells are set to record the highest CAGR, because a CAR points the cells at a defined antigen instead of relying on innate recognition, the approach follows the CAR-T model regulators have already approved while keeping the safety of donor NK cells, and receptor-modified programs now draw most development capital. Gene-edited cells target checkpoint and signaling pathways that dampen activity, while memory-like cells are designed to stay active for longer.
By cell source, the NK cell therapy market is segmented into cord blood derived, peripheral blood derived, induced pluripotent stem cell (iPSC) derived, cell line derived, and other sources. Cord blood derived products lead in 2026, since cord blood needs no elective donor procedure, banks make units available without a new collection for each batch, and many clinical programs use it. iPSC-derived products are set to grow the fastest, as one edited line can be expanded indefinitely, consistency comes from the process rather than the donor, and scheduled supply suits multi-dose regimens. Cell lines offer unlimited uniform supply but must be irradiated before infusion, which limits their activity.
By cell origin, the NK cell therapy market is segmented into allogeneic and autologous. Allogeneic products hold the largest share in 2026 and are also set to grow the fastest, as donor NK cells do not cause graft-versus-host disease, a single batch can serve many patients, and products can be stocked and shipped ahead of need. Autologous treatment keeps a role where national rules allow clinic-based treatment before approval, mainly in South Korea and Japan, but each patient needs a separate collection and production run.
By indication, the NK cell therapy market is segmented into hematological malignancies (acute myeloid leukemia, lymphoma, and multiple myeloma), solid tumors, infectious diseases, autoimmune diseases, and other indications. Hematological malignancies lead in 2026, as evidence is easiest to generate in blood cancers, infused cells reach the disease without penetrating a tumor mass, and most trials run in these settings. Solid tumors are set to record the highest CAGR, since tumor cells that lower HLA expression to escape T cells become easier NK cell targets, T cell approaches have struggled in many solid cancers, and patient numbers are far larger. Infectious disease programs focus on viral infections in immunocompromised patients.
By combination approach, the NK cell therapy market is segmented into monotherapy, combination with monoclonal antibodies, combination with checkpoint inhibitors, and combination with cytokines. Monotherapy holds the largest share in 2026, as early trials first need to show the cells are active on their own. Antibody combinations are set to grow the fastest, because NK cells drive antibody-dependent cellular cytotoxicity, the infused dose strengthens an antibody already in use, and the therapy fits a pathway clinicians and payers accept. Cytokine combinations such as interleukin-15 extend the period the cells stay active.
By end user, the NK cell therapy market is segmented into hospitals & cancer centers, specialty clinics, and academic & research institutes. Hospitals & cancer centers lead in 2026, since trials run at sites with cell therapy expertise and infusions need conditioning and close monitoring. Specialty clinics are set to grow the fastest, as low graft-versus-host risk and lighter conditioning allow treatment outside a transplant unit, and parts of Asia permit clinic-based treatment before approval. Academic and research institutes also hold a meaningful part of current activity.
Regional Analysis
The report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, spanning 13 countries, the GCC countries, and four rest-of-region groups. The regional analysis of the NK cell therapy market considers clinical trial activity, manufacturing and process development spending, treating center capability, and the regulatory frameworks that govern access.North America holds the largest share of the global NK cell therapy market in 2026. The region hosts most development programs and trials, the manufacturing and process development spending that supports them, and the treating centers with the deepest cell therapy experience, even though the FDA has not yet approved an NK cell product. The U.S. accounts for nearly all of the regional market, while Canada contributes mainly through academic programs.
Asia-Pacific is set to grow at the highest CAGR, supported by frameworks that allow treatment before marketing authorization, including South Korea's 2026 reclassification of autologous immune cell treatment and Japan's conditional pathway for regenerative medicine products. South Korea and Japan lead the region, and China adds a large number of clinical programs. Treatment volumes in Asia-Pacific exceed those in North America, but clinic-delivered treatment is priced well below clinical-stage supply. Europe's position rests on academic centers and programs in the Netherlands, Germany, and the Nordic countries, while Latin America and the Middle East & Africa remain small markets served by a limited number of private clinics.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, and the competitive dashboard, together with pipeline analysis by source and modification and benchmarking by supply reliability, doses per course, persistence evidence, and antibody partnerships. Company profiles include business overviews, financial performance, product portfolios, strategic developments, and SWOT analyses.The NK cell therapy market consists almost entirely of clinical-stage developers, best grouped by the cell source they use: iPSC lines that supply material to a schedule, cord blood backed by existing banks, and peripheral blood for autologous treatment under national frameworks. Large pharmaceutical companies mostly take part through partnerships and licensing. With products aimed at different antigens, indications, and combinations, companies currently compete for funding, clinical sites, and antibody partners, not for patients. Supply reliability across a multi-dose course is the main differentiator, followed by persistence evidence and antibody partnerships, and the first approval is expected to set the evidence standard and reference regimen for the field.
Key companies profiled in the report include Fate Therapeutics, Inc. (U.S.), Nkarta, Inc. (U.S.), Century Therapeutics, Inc. (U.S.), Artiva Biotherapeutics, Inc. (U.S.), ImmunityBio, Inc. (U.S.), NKGen Biotech, Inc. (U.S.), Celularity Inc. (U.S.), Indapta Therapeutics, Inc. (U.S.), Wugen, Inc. (U.S.), Shoreline Biosciences, Inc. (U.S.), Gamida Cell Ltd. (Israel), Glycostem Therapeutics B.V. (Netherlands), Takeda Pharmaceutical Company Limited (Japan), Takara Bio Inc. (Japan), and GC Cell Corporation (South Korea).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global NK cell therapy market.
- Explains how off-the-shelf supply, antibody combinations, iPSC manufacturing, and Asian regulatory pathways are shaping growth.
- Assesses the impact of short persistence, repeat dosing, and manufacturing volume on commercial potential.
- Identifies high-growth opportunities across all six segmentations and every region and country covered.
- Tracks CAR-NK, gene-edited, and memory-like NK cell programs and the shift toward scheduled cell sources.
- Benchmarks leading developers by cell source, supply reliability, doses per course, persistence evidence, and partnerships.
- Supports pipeline planning, partnering, licensing, manufacturing investment, and market entry decisions for developers, pharmaceutical companies, and investors.
Key Questions Answered
- How big is the global NK cell therapy market today, and how will it grow through 2036?
- How is revenue generated in a market where no NK cell therapy has yet received FDA approval?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How are developers addressing short NK cell persistence, and what does repeat dosing mean for manufacturing and pricing?
- Which product types, cell sources, indications, combination approaches, and end users will grow the fastest?
- How will CAR-NK cells and iPSC-derived products change the development landscape?
- How do regulatory changes in South Korea and Japan affect access to autologous NK cell treatment?
- Which regions and countries offer the most attractive business opportunities?
- Who are the leading developers, and how do they compare on supply, persistence evidence, and partnerships?
Table of Contents
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Insights
5. Global NK Cell Therapy Market Assessment, by Product Type
6. Global NK Cell Therapy Market Assessment, by Cell Source
7. Global NK Cell Therapy Market Assessment, by Cell Origin
8. Global NK Cell Therapy Market Assessment, by Indication
9. Global NK Cell Therapy Market Assessment, by Combination Approach
10. Global NK Cell Therapy Market Assessment, by End User
11. Global NK Cell Therapy Market Assessment, by Geography
12. Competitive Landscape
13. Company Profiles
14. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Fate Therapeutics, Inc.
- Nkarta, Inc.
- Century Therapeutics, Inc.
- Artiva Biotherapeutics, Inc.
- ImmunityBio, Inc.
- NKGen Biotech, Inc.
- Celularity Inc.
- Indapta Therapeutics, Inc.
- Wugen, Inc.
- Shoreline Biosciences, Inc.
- Gamida Cell Ltd.
- Glycostem Therapeutics B.V.
- Takeda Pharmaceutical Company Limited
- Takara Bio Inc.
- GC Cell Corporation
